Publications by authors named "Coralie Amadou"
Aims: This study aimed to compare 12-month metabolic outcomes in patients with type 1 diabetes (T1D) treated with either MiniMed 780G (Guardian 4) or Control-IQ (Dexcom G6) automated insulin delivery (AID) systems and identify interaction with patient characteristics.
Materials And Methods: We conducted a single-centre, retrospective study including all patients (aged ≥16) with T1D who were started on either MiniMed 780G or Control-IQ between January 2021 and October 2022 and continued for ≥12 months. We used propensity score matching to compare the average marginal effects between MiniMed 780G and Control-IQ regarding the primary outcome (time in range [TIR]) and secondary outcomes (time below range [TBR], glucose monitoring indicator [GMI] and coefficient of variation [CV]) after 12 months.
Objective: Childhood-onset type 1 diabetes (T1D) is associated with perinatal factors, but data related to adult-onset T1D are scarce. This study aimed at investigating the association between early-life factors and adult-onset T1D in a Swedish nationwide cohort and family-based study.
Research Design And Methods: We included 1,813,415 individuals aged ≥18 years, born in Sweden 1983 to 2002, followed until 2020.
Background: To measure the association of prematurity and non-preterm low birth weight (LBW) with several long-term health outcomes.
Methods: We selected adult participants from the Constances cohort. Associations between preterm birth (<37 weeks versus ≥37 weeks) and outcomes were measured using modified Poisson regression with adjustment for participant age and parental history.
Background: We aimed to measure the variance due to examination conditions during the first sessions of objective structured clinical examinations (OSCEs) performed at a French medical school and identify factors associated with student success.
Methods: We conducted a retrospective, observational study using data from the first three OSCEs sessions performed at Paris-Saclay medical school in 2021 and 2022. For all sessions (each organized in 5 parallel circuits), we tested a circuit effect using a linear mixed-effects model adjusted for sex and the average academic level of students (according to written tests).
Background investigated whether Ramadan, a yearly religious fasting lasting for 1 month, could challenge the metabolic control obtained under a hybrid closed-loop (HCL) therapy in patients living with type 1 diabetes (T1D). This real-life prospective study involved 20 patients with T1D and moderate to high-risk score of adverse events at baseline. We compared continuous glucose monitoring (CGM) parameters under HCL therapy 1 month before and during the Ramadan fasting month.
View Article and Find Full Text PDFPancreatic diabetes is associated with glycemic variability, poor metabolic control, and reduced quality of life. Though hybrid closed-loop (HCL) insulin delivery systems were not originally developed for these types of diabetes, they could address the therapeutic challenge. We aimed to evaluate long-term metabolic control in ten adult patients (mean ± SD age: 59 ± 12) treated with HCL insulin delivery systems for pancreatitis or pancreatectomy-induced diabetes.
View Article and Find Full Text PDFTo evaluate the percentage of patients with type 1 diabetes (T1D) and very poor metabolic control who would agree to be treated with a hybrid closed-loop (HCL) insulin delivery system, and to assess metabolic improvement and safety. In a single center, we identified all patients aged >18 years with hemoglobin A1c (HbA1c) >11% (97 mmol/mol) before HCL treatment. We collected metabolic control and safety data up to 1 year post-HCL in those who accepted HCL after it was proposed to them.
View Article and Find Full Text PDFBackground: We assessed the performance and patient satisfaction of a new insulin patch pump, the A7+TouchCare (Medtrum), compared with the Omnipod system.
Methods: This multicenter, randomized, open-label, controlled study enrolled 100 adult patients with type 1 or type 2 diabetes mellitus (A1C ≥ 6.5% and ≤ 9.
Article Synopsis
- DBLG1 is a commercially available closed-loop system for type 1 diabetes, and this study reviews its impact on patient outcomes and interoperability using existing data.
- Data was collected from 6859 adult patients through randomized controlled trials and real-life surveys conducted between 2017 and 2022, demonstrating significant improvements in time in range (TIR) and reductions in hypoglycemia.
- The results indicate that DBLG1 is effective, safe, and compatible with various pump systems, consistently showing enhanced performance across different European populations.
Introduction: Long-term consequences of impaired fetal growth are well documented for cardiometabolic outcomes. We propose an outcome-wide analysis of the association between birth weight (BW) and long-term health in a large contemporary adult cohort.
Methods: The study included 73,315 participants under 60 years with a reliable BW from the French nationwide Constances cohort.
Article Synopsis
- The study aimed to determine if diabetes is a risk factor for severe COVID-19 outcomes, independent of age and other health conditions, as diabetes is often seen in older individuals.
- Conducted as part of the CORONADO initiative, the research matched 2210 COVID-19 patients with and without diabetes by age, sex, and admission date, assessing outcomes like death and the need for invasive mechanical ventilation.
- Results showed that diabetes patients had higher rates of adverse outcomes within both 7 and 28 days of hospital admission, indicating that diabetes is a significant risk factor for severe COVID-19 complications regardless of age and comorbidity.
Background And Aims: The association between birth weight (BW) and metabolic outcomes has been described since the 1980s but NAFLD has been rarely studied. This study aimed to investigate the association between BW and NAFLD occurrence in adult subjects.
Approach And Results: The study population consisted of participants from the French nationwide Constances cohort from 2012 to 2019.
Objective: Insulin pump discontinuation has mostly been studied in children and adolescents living with diabetes. We aimed to assess the rate of insulin pump continuation in a population of adult patients with diabetes, at 18 months after initiation; determine the factors associated with pump discontinuation; and develop a simple prediction model.
Methods: This single-center, retrospective study included all adult patients with type 1 diabetes or type 2 diabetes who started insulin pump treatment between January 2015 and June 2018.
Background: To evaluate the impact of switching from U-100 to U-500 insulin in patients with type 2 diabetes mellitus (T2DM) uncontrolled with continuous subcutaneous insulin infusion (CSII) by pump.
Methods: We retrospectively collected data from patients with T2DM, treated by U-100 CSII, who were switched to U-500 regular insulin where haemoglobin A1c (Hb) was >8% and/or insulin total daily dose (TDD) was >100 UI/d. Data collection from patient medical records included Hb, lipid levels, liver biomarkers, weight, TDD, declared hypoglycaemic episodes and measured by continuous glucose monitoring (CGM).
COVID-19 pandemic lockdown in young people with type 1 diabetes: Positive results of an unprecedented challenge for patients through telemedicine and change in use of continuous glucose monitoring.
Prim Care Diabetes
October 2021
There has been little data published related to glucose control in adolescents and young adults with type 1 diabetes (T1D) during lockdown, but rarely focusing on telemedicine's role. During this unpreceded period, glucose control and self-monitoring improved in our young patients, with better results associated with telemedicine.
View Article and Find Full Text PDFArticle Synopsis
- The study examined sex differences in severe outcomes of COVID-19 among adults with diabetes, analyzing data from 2,380 hospitalized patients.
- Findings revealed that females had a lower risk of invasive mechanical ventilation, death, and ICU admission compared to males, although this female advantage was less evident in overall in-hospital mortality.
- The research highlighted specific predictors of death linked to sex, emphasizing the need for tailored COVID-19 management strategies based on biological differences.
A post hoc analysis of the Diabeloop WP7 multicentre, randomized controlled trial was performed to investigate the efficacy of the Diabeloop Generation-1 (DBLG1) closed-loop system in controlling the hypoglycaemia induced by physical activity (PA) in real-life conditions. Glycaemic outcomes were compared between days with and without PA in 56 patients with type 1 diabetes (T1D) using DBLG1 for 12 weeks. After the patient announces a PA, DBLG1 reduces insulin delivery and, if necessary, calculates the amount of preventive carbohydrates (CHO).
View Article and Find Full Text PDFArticle Synopsis
- The CORONADO study examines outcomes in diabetic patients hospitalized due to COVID-19, focusing on hospital discharge and death rates within 28 days of admission.
- The study analyzed data from 2,796 patients, revealing that 50.2% were discharged and 20.6% died; factors influencing discharge included younger age and metformin use, while complications and severity indicators were linked to a higher risk of death.
- The findings aim to identify key prognostic factors to guide clinical decision-making for diabetic patients during the pandemic.
Objective: To analyze safety and efficacy of the Diabeloop Generation 1 (DBLG1) hybrid closed-loop artificial pancreas system in patients with type 1 diabetes in real-world conditions.
Research Design And Methods: After a 1-week run-in period with their usual pump, 25 patients were provided the commercial DBLG1 system. The results are presented on time in range (TIR) and HbA over 6 months.
Article Synopsis
- The study aimed to investigate the effects of prior metformin use on the health outcomes of type 2 diabetes patients hospitalized for COVID-19.
- An analysis of 2,449 patients showed that metformin users generally had better survival rates and lower mortality compared to non-users, particularly noted at days 7 and 28 after admission.
- The conclusion suggests that metformin may reduce the risk of death in diabetes patients with COVID-19, indicating its potential beneficial effects during hospitalization.
Objective: To assess the improvement in the management of diabetes and its complications based on the evolution of hospitalisation rates for diabetic foot ulcer (DFU) and lower extremity amputation (LEA) in individuals with diabetes in France.
Methods: Data were provided by the French national health insurance general scheme from 2008 to 2014. Hospitalisations for DFU and LEA were extracted from the SNIIRAM/SNDS French medical and administrative database.